SCHEMBL5378063

SCHEMBL5378063

Cc1ccc(-c2ccc(-c3cn4nc(N)ccc4n3)nn2)cc1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.40
MAPT P10636 3/20 0.39
TP53 P04637 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PIK3CG P48736 3/20 0.37
DYRK1A Q13627 1/20 0.35
LRRK2 Q5S007 3/20 0.35
JAK2 O60674 1/20 0.35
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
USP2 O75604 1/20 0.33
NPC1 O15118 1/20 0.33
MAP3K14 Q99558 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10284772 0.91 APP (0.47) APPMAPTTP53SMN1; SMN2PIK3CG
SCHEMBL2540334 0.85 APP (0.42) APPMAPTTP53SMN1; SMN2PIK3CG
SCHEMBL5306486 0.80 APP (0.38) APPMAPTTP53SMN1; SMN2PIK3CG
SCHEMBL2538113 0.79 FEN1 (0.39) APPMAPTTP53SMN1; SMN2PIK3CG
SCHEMBL16009643 0.71 CYP1A2 (0.47) MAPTSMN1; SMN2PIK3CGDYRK1AJAK2
SCHEMBL9955992 0.70 CSNK1D (0.41) MAPTTP53SMN1; SMN2PIK3CGPIK3CD
SCHEMBL2540879 0.69 SMN1; SMN2 (0.41) APPMAPTTP53SMN1; SMN2PIK3CG
SCHEMBL18281419 0.69 SMN1; SMN2 (0.39) APPMAPTTP53SMN1; SMN2PIK3CG
SCHEMBL2536912 0.69 RAB9A (0.48) APPMAPTTP53SMN1; SMN2PIK3CA
SCHEMBL18613326 0.69 ALDH1A3 (0.56) APPMAPTTP53SMN1; SMN2PIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10933049-B2 Mobilizing agents and uses therefor THE UNIVERSITY OF QUEENSLAND (AU) 2021-03-02 US disclosed
US-20180185328-A1 MOBILIZING AGENTS AND USES THEREFOR THE UNIVERSITY OF QUEENSLAND (AU) 2018-07-05 US disclosed
EP-3302710-A1 MOBILIZING AGENTS AND USES THEREFOR The University of Queensland (AU) 2018-04-11 EP disclosed
WO-2016191811-A1 MOBILIZING AGENTS AND USES THEREFOR THE UNIVERSITY OF QUEENSLAND (AU) 2016-12-08 WO disclosed
WO-2007034282-A2 DIARYL-IMIDAZOLE COMPOUNDS CONDENSED WITH A HETEROCYCLE AS C3A RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180185328-A1 MOBILIZING AGENTS AND USES THEREFOR C3AR1, CSF3R, C5AR1 APP 4680/4885MAPT 4884/4885TP53 2107/4885
US-10933049-B2 Mobilizing agents and uses therefor C3AR1, CSF3R, C5AR1 APP 4680/4885MAPT 4884/4885TP53 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.